Biomarkers /
NR4A3
Overview
Nuclear receptor subfamily 4, group A, member 3 (NR4A3) is a gene that encodes a protein that functions as a transcriptional activator. Fusion mutations are observed in this gene.
NR4A3 is altered in 0.05% of all cancers with extraskeletal myxoid chondrosarcoma, lung adenocarcinoma, myxoid chondrosarcoma, astrocytoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in NR4A3 are NR4A3-EWSR1 Fusion (0.04%), NR4A3 Fusion (0.02%), NR4A3 Q5P (0.02%), NR4A3 V4I (0.02%), and NR4A3 V4L (0.02%) [3].
Clinical Trials
Significance of NR4A3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.